Items where authors include "Hernandez-Alava, M."

Article

Hernandez-Alava, M. orcid.org/0000-0003-4474-5883 and Pudney, S. (2022) Mapping between EQ-5D-3L and EQ-5D-5L: A survey experiment on the validity of multi-instrument data. Health Economics, 31 (6). pp. 923-939. ISSN 1057-9230

Pennington, B. orcid.org/0000-0002-1002-022X, Hernandez-Alava, M., Pudney, S. et al. (1 more author) (2018) The Impact of Moving from EQ-5D-3L to -5L in NICE Technology Appraisals. PharmacoEconomics. ISSN 1170-7690

Hernandez-Alava, M. and Pudney, S. (2017) Econometric modelling of multiple self-reports of health states: The switch from EQ-5D-3L to EQ-5D-5L in evaluating drug therapies for rheumatoid arthritis. Journal of Health Economics, 55. pp. 139-152. ISSN 0167-6296

Stevenson, M.D. orcid.org/0000-0002-3099-9877, Wailoo, A.J. orcid.org/0000-0002-9324-1617, Tosh, J.C. et al. (8 more authors) (2017) The cost-effectiveness of sequences of biological disease-modifying antirheumatic drug treatment in England for patients with rheumatoid arthritis who can tolerate methotrexate. Journal of Rheumatology, 44 (7). pp. 973-980. ISSN 0315-162X

Stevenson, M. orcid.org/0000-0002-3099-9877, Archer, R., Tosh, J. et al. (9 more authors) (2016) Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Health Technology Assessment, 20 (35). pp. 1-610. ISSN 1366-5278